Table 4.
Healthcare Resource Use in Patients Hospitalized with cSSTI According to Clinical Response to Ceftaroline Fosamil
| Outcome Measure | Clinical Response to Ceftaroline Fosamila | |||
|---|---|---|---|---|
| Response (n = 118) | No Response (n = 14) | |||
| Length of stay, days | Mean (SD) | Median (range) | Mean (SD) | Median (range) |
| In hospital | 18.6 (23.7) | 11 (3–162) | 26.2 (14.8) | 25 (5–58) |
| In ICUb | 1.1 (4.6) | 0 (0–41) | 1.5 (3.2) | 0 (0–10) |
| Hospital costs, USD | ||||
| Standard hospitalc | 5196.2 (9070.4) | 1904.3 (250.9–58,904.8) | 8991.7 (7673.5) | 8185.6 (418.2–24,987.6) |
| Advanced-level hospitalb,d | 20,257.2 (36,809.7) | 7281.0 (1130.8–263,640.4) | 35,134.3 (29,681.8) | 31,859.8 (1884.6–97,256.1) |
Notes: aClinical response defined as ≥20% reduction from baseline infection area and cessation of spread measured by total infection area. bn = 14 patients with response and n = three non-responders were reported to receive ICU/advanced-level hospital care. cStandard hospital cost: total time in hospital multiplied by per diem rate of standard hospital general ward. dAdvanced hospital cost: total time in hospital multiplied by per diem rate of hospitals providing the highest level of medical services.
Abbreviations: cSSTI, complicated skin and soft tissue infections; ICU, intensive care unit; SD, standard deviation; USD, US dollars.